title: From evolution to revolution: miRNAs as pharmacological targets for modulating cholesterol efflux and reverse cholesterol transport.
abstract: There has been strong evolutionary pressure to ensure that an animal cell maintains levels of cholesterol within tight limits for normal function. Imbalances in cellular cholesterol levels are a major player in the development of different pathologies associated to dietary excess. Although epidemiological studies indicate that elevated levels of high-density lipoprotein (HDL)-cholesterol reduce the risk of cardiovascular disease, recent genetic evidence and pharmacological therapies to raise HDL levels do not support their beneficial effects. Cholesterol efflux as the first and probably the most important step in reverse cholesterol transport is an important biological process relevant to HDL function. Small non-coding RNAs (microRNAs), post-transcriptional control different aspects of cellular cholesterol homeostasis including cholesterol efflux. miRNA families miR-33, miR-758, miR-10b, miR-26 and miR-106b directly modulates cholesterol efflux by targeting the ATP-binding cassette transporter A1 (ABCA1). Pre-clinical studies with anti-miR therapies to inhibit some of these miRNAs have increased cellular cholesterol efflux, reverse cholesterol transport and reduce pathologies associated to dyslipidemia. Although miRNAs as therapy have benefits from existing antisense technology, different obstacles need to be solved before we incorporate such research into clinical care. Here we focus on the clinical potential of miRNAs as therapeutic target to increase cholesterol efflux and reverse cholesterol transport as a new alternative to ameliorate cholesterol-related pathologies.
authors: IMDEA Food Institute, CEI UAM+CSIC, 28049 Madrid, Spain. alberto.davalos@imdea.org
authors: Alberto
authors: A
authors: Dávalos
authors: Carlos
authors: C
authors: Fernández-Hernando
mesh_terms: D000818:Animals; D005075:Biological Evolution; D001692:Biological Transport; D002784:Cholesterol / Q000096:biosynthesis / Q000097:blood / Q000378:metabolism*; D008076:Cholesterol, HDL / Q000096:biosynthesis / Q000097:blood / Q000378:metabolism; D005786:Gene Expression Regulation; D018390:Gene Targeting / Q000379:methods*; D006801:Humans; D006937:Hypercholesterolemia / Q000235:genetics* / Q000378:metabolism / Q000628:therapy*; D035683:MicroRNAs / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics*; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use
chemical_list: D008076:Cholesterol, HDL; D035683:MicroRNAs; D016376:Oligonucleotides, Antisense; D002784:Cholesterol
keywords: ABCA1; Cholesterol efflux; HDL; miRNAs